Product Description
JNK1 (c-Jun N-terminal kinase 1), also known as MAPK8 (mitogen-activated protein kinase 8), is a member of the serine/threonine protein kinase family (MAPK subfamily) that plays a pivotal role in stress signaling, apoptosis, inflammation, and cell differentiation. JNK1 is activated by various stimuli including cytokines (e.g., TNFα, IL-1β), oxidative stress, UV radiation, and growth factor deprivation, leading to phosphorylation of downstream targets such as c-Jun, ATF2, and ELK1, thereby regulating AP-1 transcriptional activity and modulating gene expression involved in cell survival and death. Beyond its role in normal cellular stress responses and immune regulation, dysregulation of JNK1 signaling—through hyperactivation or aberrant expression—is closely associated with neurodegenerative diseases (e.g., Alzheimer's and Parkinson's diseases), chronic inflammation, insulin resistance, type 2 diabetes, and multiple cancers (including hepatocellular carcinoma and glioblastoma), making it a highly validated target for anti-inflammatory therapy, metabolic disease treatment, and cancer drug discovery.
Screeningbio’s JNK1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying JNK1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: JNK1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the JNK1 kinase.
Data